title: Comparison of intravenous adenosine and intravenous regadenoson for the measurement of pressure-derived coronary fractional flow reserve.
abstract: OBJECTIVE
  Defining the clinical and physiologic significance of an intermediate coronary artery stenosis is aided by measurement of fractional flow reserve (FFR). Adenosine is the most common agent used in the cardiac catheterisation laboratory for the measurement of FFR. Regadenoson, a selective adenosine receptor agonist, with fewer side effects than adenosine has been used extensively in stress testing to induce hyperaemia. We postulated that FFR measurements would be equivalent following administration of regadenoson and adenosine.
  
  
  RESULTS
  Twenty patients with an angiographic intermediate coronary artery stenosis (50% to 80%) were included in the study. FFR was measured during three minutes of intravenous (IV) adenosine infusion and for five minutes after an injection of regadenoson. The mean difference between the FFR measured by IV adenosine and IV regadenoson was 0.0040 (min -0.04, max +0.04, standard deviation [SD] 0.025). There was a strong linear correlation between the FFR measured by IV adenosine and IV regadenoson (R2 linear=0.933). The FFR at maximum hyperaemia was achieved earlier using regadenoson than adenosine (59±24.5 sec vs. 93±44.5 sec, p=0.01).
  
  
  CONCLUSIONS
  Regadenoson produces similar pressure-derived FFR compared to IV adenosine infusion.
authors.affiliation: Cardiovascular Diseases, Cardiac Catherization Laboratory, Albert Einstein Medical Center and the Einstein Institute for Heart and Vascular Health, Philadelphia, PA 19141, USA.
authors.forename: Pradeep
authors.initials: P
authors.lastname: Arumugham
authors.forename: Vincent M
authors.initials: VM
authors.lastname: Figueredo
authors.forename: Parul B
authors.initials: PB
authors.lastname: Patel
authors.forename: D Lynn
authors.initials: DL
authors.lastname: Morris
mesh_terms: D000241:Adenosine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D058908:Adenosine A2 Receptor Agonists / Q000494:pharmacology*; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D053805:Fractional Flow Reserve, Myocardial / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011687:Purines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D058908:Adenosine A2 Receptor Agonists; D011687:Purines; D011720:Pyrazoles; C430916:regadenoson; D000241:Adenosine